Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

First-Line Pembrolizumab/Placebo Plus Trastuzumab and Chemotherapy in Her2-Positive Advanced Gastric Cancer: KEYNOTE-811

Open access
Chung, Hyun Cheol, Bang, Yung-Jue, S Fuchs, Charles, Qin, Shu-Kui, Satoh, Taroh, Shitara, Kohei, Tabernero, Josep, Van Cutsem, Eric, Alsina, Maria, Cao, Zhu Alexander, Lu, Jia, Bhagia, Pooja, Shih, Chie-Schin, Janjigian, Yelena Y · 2021 · Future Oncology

Abstract

Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Clinical trial registration: NCT03615326 (ClinicalTrials.gov).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon-2020-0737

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 165

Metadata

Authors
Chung, H. C., Bang, Y.-J., S Fuchs, C., Qin, S.-K., Satoh, T., Shitara, K., Tabernero, J., Van Cutsem, E., Alsina, M., Cao, Z. A., Lu, J., Bhagia, P., Shih, C.-S., & Janjigian, Y. Y.
Venue
Future Oncology
Published
2020-11-10
Volume
17
Issue
5
Pages
491-501
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W3098108773
Cited by
165
References
2
FWCI
13.91
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-Line Pembrolizumab/Placebo Plus Trastuzumab and Chemotherapy in Her2-Positive Advanced Gastric Cancer: KEYNOTE-811. https://app.cochat.ai/papers/10.2217/fon-2020-0737
The paper
Chung, H. C., Bang, Y.-J., S Fuchs, C., Qin, S.-K., Satoh, T., Shitara, K., Tabernero, J., Van Cutsem, E., Alsina, M., Cao, Z. A., Lu, J., Bhagia, P., Shih, C.-S., & Janjigian, Y. Y. (2021). First-Line Pembrolizumab/Placebo Plus Trastuzumab and Chemotherapy in Her2-Positive Advanced Gastric Cancer: KEYNOTE-811. Future Oncology. https://doi.org/10.2217/fon-2020-0737

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.